Sutro Biopharma
STRO
58 hedge funds and large institutions have $134M invested in Sutro Biopharma in 2019 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 20 increasing their positions, 15 reducing their positions, and 3 closing their positions.
300% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 3
33% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 15
18% more funds holding
Funds holding: 49 → 58 (+9)
5% more capital invested
Capital invested by funds: $128M → $134M (+$6.55M)
0.24% more ownership
Funds ownership: 4.92% → 5.15% (+0.24%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$3.55M |
| 2 |
BlackRock
New York
|
+$2.52M |
| 3 |
State Street
Boston,
Massachusetts
|
+$675K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$538K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$421K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.35M |
| 2 |
SCM
Sio Capital Management
New York
|
-$658K |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$571K |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$518K |
| 5 |
PCM
Pentwater Capital Management
Naples,
Florida
|
-$298K |
STRO Hedge Fund Activity: Q2 2019 in Review
58 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q2 2019, worth a combined $134M — up 5.1% from $128M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new STRO positions and 3 closed out — a net gain of 9 holders — while 20 added to existing stakes and 15 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $3.55M. The largest seller was Fidelity Investments, cutting an estimated $1.35M.
- 58 institutional investors held Sutro Biopharma (STRO) as of Q2 2019, up from 49 in Q1 2019.
- Funds reported $134M of Sutro Biopharma stock for Q2 2019, up 5.1% quarter-over-quarter.
- 12 funds opened new Sutro Biopharma positions in Q2 2019 and 3 closed out, a net change of +9 holders.
- The largest Sutro Biopharma buyer in Q2 2019 was Point72 Asset Management, an estimated $3.55M added.
- The largest Sutro Biopharma seller in Q2 2019 was Fidelity Investments, an estimated $1.35M sold.
Based on aggregated 13F filings for Q2 2019.